Martingale Asset Management L P Trims Stake in QIAGEN N.V. $QGEN

Key Points

• Martingale Asset Management L P reduced its stake in Qiagen N.V. by 33.1%, selling 87,406 shares, and now owns 176,283 shares worth approximately $7.08 million.
• During the same period, other institutional investors, including Wealth Enhancement Advisory Services LLC and Wells Fargo, have also modified their holdings, indicating ongoing interest in Qiagen stocks.
• Research firms have provided mixed ratings for Qiagen, with three firms rating it as a "Buy" and eight giving it a "Hold", while UBS raised their price target to $50 and Bank of America to $53.

Martingale Asset Management L P lowered its position in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 33.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 176,283 shares of the company's stock after selling 87,406 shares during the period. Martingale Asset Management L P owned 0.08% of QIAGEN worth $7,078,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd purchased a new stake in QIAGEN during the 1st quarter worth about $94,000. Tower Research Capital LLC TRC boosted its holdings in shares of QIAGEN by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after buying an additional 2,204 shares in the last quarter. GAMMA Investing LLC grew its position in shares of QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares during the last quarter. Federated Hermes Inc. purchased a new position in shares of QIAGEN in the 1st quarter valued at $150,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in QIAGEN during the 4th quarter worth $202,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on QGEN shares. Wall Street Zen downgraded shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. UBS Group boosted their target price on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Bank of America upped their target price on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Barclays initiated coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target on the stock. Finally, Cowen reiterated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $49.69.

QIAGEN Stock Performance

NYSE QGEN traded up $0.5840 on Friday, hitting $49.7140. 882,883 shares of the company's stock were exchanged, compared to its average volume of 1,336,129. The firm has a market cap of $11.05 billion, a price-to-earnings ratio of 29.37, a P/E/G ratio of 2.61 and a beta of 0.64. The firm's 50-day moving average price is $48.61 and its two-hundred day moving average price is $43.90. QIAGEN N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the business earned $0.55 earnings per share. The company's revenue for the quarter was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts expect that QIAGEN N.V. will post 2.26 EPS for the current year.

QIAGEN Dividend Announcement

The company also recently declared a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date was Wednesday, July 2nd. This represents a dividend yield of 52.0%. QIAGEN's dividend payout ratio is currently 14.79%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.